Search Results

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.

Domain Therapeutics (“Domain” or “the Company”) today announces that latest preclinical data on DT-9045, a novel protease-activated receptor 2 (PAR2) Negative Allosteric Modulator candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.

Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET.

Pieris Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024.